Abstract
There is compelling evidence that the gut microbiota functions as an endocrine organ through the production of various metabolites with hormone-like properties that play multifaceted roles in host metabolism. It is increasingly appreciated that gut dysbiosis, which disturbs the production and utilization of microbial metabolites, is a major determinant of several metabolic diseases. In this chapter, we discuss the influence of some of these microbial-related metabolites on host (patho)physiological processes known to be involved in the development of metabolic disorders, such as obesity and its related comorbidities. The pace of progress in this field is rapid, and a deeper understanding of the mechanistic roles that microbial metabolites play in the interaction between the host and gut microbiota will undoubtedly reveal new insights into the etiology of metabolic disorders. Microbial metabolites are also emerging as useful biomarkers and clinical tools to evaluate disease predisposition and progression, and further research will hopefully define new uses of microbial metabolites for not only the treatment of metabolic disease but also its prevention.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Brooks GA. The science and translation of lactate shuttle theory. Cell Metab. 2018;27(4):757–85. https://doi.org/10.1016/J.CMET.2018.03.008.
Callender C, Attaye I, Nieuwdorp M. The interaction between the gut microbiome and bile acids in Cardiometabolic diseases. Meta. 2022;12(1):65. https://doi.org/10.3390/metabo12010065.
Carbonero F, Benefiel AC, Alizadeh-Ghamsari AH, Gaskins HR. Microbial pathways in colonic sulfur metabolism and links with health and disease. Front Physiol. 2012;3:448. https://doi.org/10.3389/fphys.2012.00448.
Certo M, Llibre A, Lee W, Mauro C. Understanding lactate sensing and signalling. Trends Endocrinol Metab. 2022;33(10):722–35. https://doi.org/10.1016/J.TEM.2022.07.004.
Chen J, Thomsen M, Vitetta L. Interaction of gut microbiota with dysregulation of bile acids in the pathogenesis of nonalcoholic fatty liver disease and potential therapeutic implications of probiotics. J Cell Biochem. 2019;120(3):2713–20. https://doi.org/10.1002/jcb.27635.
Cho CE, Caudill MA. Trimethylamine-N-oxide: friend, foe, or simply caught in the cross-fire? Trends Endocrinol Metab. 2017;28(2):121–30. https://doi.org/10.1016/J.TEM.2016.10.005.
Comas F, Moreno-Navarrete JM. The impact of H2S on obesity-associated metabolic disturbances. Antioxidants. 2021;10(5):633. https://doi.org/10.3390/ANTIOX10050633.
Ðanić M, Stanimirov B, Pavlović N, Goločorbin-Kon S, Al-Salami H, Stankov K, Mikov M. Pharmacological applications of bile acids and their derivatives in the treatment of metabolic syndrome. Front Pharmacol. 2018;9:1382. https://doi.org/10.3389/fphar.2018.01382.
Devaux CA, Million M, Raoult D. The Butyrogenic and lactic bacteria of the gut microbiota determine the outcome of allogenic hematopoietic cell transplant. Front Microbiol. 2020;11:1642. https://doi.org/10.3389/fmicb.2020.01642.
Fernández-Veledo S, Vendrell J. Gut microbiota-derived succinate: friend or foe in human metabolic diseases? Rev Endocr Metab Disord. 2019;20(4):439–47. https://doi.org/10.1007/s11154-019-09513-z.
Fernández-Veledo S, Ceperuelo-Mallafré V, Vendrell J. Rethinking succinate: an unexpected hormone-like metabolite in energy homeostasis. Trends Endocrinol Metab. 2021;32(9):680–92. https://doi.org/10.1016/J.TEM.2021.06.003.
Grüner N, Mattner J. Bile acids and microbiota: multifaceted and versatile regulators of the liver–gut axis. Int J Mol Sci. 2021;22(3):1–17. https://doi.org/10.3390/ijms22031397.
Guzior D v, Quinn RA. Review: microbial transformations of human bile acids. Microbiome. 2021;9(1):140. https://doi.org/10.1186/s40168-021-01101-1.
He J, Zhang P, Shen L, Niu L, Tan Y, Chen L, Zhao Y, Bai L, Hao X, Li X, Zhang S, Zhu L. Short-chain fatty acids and their association with signalling pathways in inflammation, glucose and lipid metabolism. Int J Mol Sci. 2020;21(17):6356. https://doi.org/10.3390/ijms21176356.
Huber-Ruano I, Calvo E, Mayneris-Perxachs J, Rodríguez-Peña MM, Ceperuelo-Mallafré V, Cedó L, Núñez-Roa C, Miro-Blanch J, Arnoriaga-Rodríguez M, Balvay A, Maudet C, García-Roves P, Yanes O, Rabot S, Grimaud GM, de Prisco A, Amoruso A, Fernández-Real JM, Vendrell J, Fernández-Veledo S. Orally administered Odoribacter laneus improves glucose control and inflammatory profile in obese mice by depleting circulating succinate. Microbiome. 2022;10(1):135. https://doi.org/10.1186/S40168-022-01306-Y.
Ilyas A, Wijayasinghe YS, Khan I, el Samaloty NM, Adnan M, Dar TA, Poddar NK, Singh LR, Sharma H, Khan S. Implications of trimethylamine N-oxide (TMAO) and betaine in human health: beyond being Osmoprotective compounds. Front Mol Biosci. 2022;9:964624. https://doi.org/10.3389/FMOLB.2022.964624.
Jones TE, Pories WJ, Houmard JA, Tanner CJ, Zheng D, Zou K, Coen PM, Goodpaster BH, Kraus WE, Dohm GL. Plasma lactate as a marker of metabolic health: implications of elevated lactate for impairment of aerobic metabolism in the metabolic syndrome. Surgery. 2019;166(5):861–6. https://doi.org/10.1016/J.SURG.2019.04.017.
Koeth RA, Levison BS, Culley MK, Buffa JA, Wang Z, Gregory JC, Org E, Wu Y, Li L, Smith JD, Tang WHW, Didonato JA, Lusis AJ, Hazen SL. γ-Butyrobetaine is a proatherogenic intermediate in gut microbial metabolism of L-carnitine to TMAO. Cell Metab. 2014;20(5):799–812. https://doi.org/10.1016/J.CMET.2014.10.006.
Koh A, de Vadder F, Kovatcheva-Datchary P, Bäckhed F. From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites. Cell. 2016;165(6):1332–45. https://doi.org/10.1016/j.cell.2016.05.041.
Konieczny RA, Kuliczkowski W. Trimethylamine N-oxide in cardiovascular disease. Adv Clin Exp Med. 2022;31(8):913–25. https://doi.org/10.17219/ACEM/147666.
Krueger ES, Lloyd TS, Tessem JS. The accumulation and molecular effects of trimethylamine N-oxide on metabolic tissues: It’s not all bad. Nutrients. 2021;13(8):2873. https://doi.org/10.3390/NU13082873.
Kumar P, Lee JH, Lee J. Diverse roles of microbial indole compounds in eukaryotic systems. Biol Rev. 2021;96(6):2522–45. https://doi.org/10.1111/brv.12765.
Louis P, Duncan SH, Sheridan PO, Walker AW, Flint HJ. Microbial lactate utilisation and the stability of the gut microbiome. Gut Microbiome. 2022;3(e3):1–16. https://doi.org/10.1017/GMB.2022.3.
Lu Y, Zhang Y, Zhao X, Shang C, Xiang M, Li L, Cui X. Microbiota-derived short-chain fatty acids: implications for cardiovascular and metabolic disease. Front Cardiovasc Med. 2022;9:900381. https://doi.org/10.3389/fcvm.2022.900381.
May KS, den Hartigh LJ. Modulation of adipocyte metabolism by microbial short-chain fatty acids. Nutrients. 2021;13(10):3666. https://doi.org/10.3390/nu13103666.
Mayeur C, Gratadoux JJ, Bridonneau C, Chegdani F, Larroque B, Kapel N, Corcos O, Thomas M, Joly F. Faecal D/L lactate ratio is a metabolic signature of microbiota imbalance in patients with short bowel syndrome. PLoS One. 2013;8(1):e54335. https://doi.org/10.1371/JOURNAL.PONE.0054335.
Molinaro A, Wahlström A, Marschall HU. Role of bile acids in metabolic control. Trends Endocrinol Metab. 2018;29(1):31–41. https://doi.org/10.1016/j.tem.2017.11.002.
Oliphant K, Allen-Vercoe E. Macronutrient metabolism by the human gut microbiome: major fermentation by-products and their impact on host health. Microbiome. 2019;7(1):91. https://doi.org/10.1186/s40168-019-0704-8.
Osuna-Prieto FJ, Martinez-Tellez B, Ortiz-Alvarez L, Di X, Jurado-Fasoli L, Xu H, Ceperuelo-Mallafré V, Núñez-Roa C, Kohler I, Segura-Carretero A, García-Lario JV, Gil A, Aguilera CM, Llamas-Elvira JM, Rensen PCN, Vendrell J, Ruiz JR, Fernández-Veledo S. Elevated plasma succinate levels are linked to higher cardiovascular disease risk factors in young adults. Cardiovasc Diabetol. 2021;20(1) https://doi.org/10.1186/S12933-021-01333-3/FIGURES/3.
Papandreou C, Moré M, Bellamine A. Trimethylamine N-oxide in relation to cardiometabolic health-cause or effect? Nutrients. 2020;12(5):1330. https://doi.org/10.3390/NU12051330.
Pegg AE. Functions of polyamines in mammals. J Biol Chem. 2016;291(29):14904–12. https://doi.org/10.1074/jbc.R116.731661.
Poland JC, Flynn CR. Bile acids, their receptors, and the gut microbiota. Physiology. 2021;36(4):235–45. https://doi.org/10.1152/PHYSIOL.00028.2020.
Portincasa P, Bonfrate L, Vacca M, de Angelis M, Farella I, Lanza E, Khalil M, Wang DQH, Sperandio M, di Ciaula A. Gut microbiota and short chain fatty acids: implications in glucose homeostasis. Int J Mol Sci. 2022;23(3):1105. https://doi.org/10.3390/ijms23031105.
Rahman MM, Rahaman MS, Islam MR, Rahman F, Mithi FM, Alqahtani T, Almikhlafi MA, Alghamdi SQ, Alruwaili AS, Hossain MS, Ahmed M, Das R, Emran TB, Uddin MS. Role of phenolic compounds in human disease: current knowledge and future prospects. Molecules. 2022;27(1):233. https://doi.org/10.3390/molecules27010233.
Ramos-Molina B, Queipo-Ortuño MI, Lambertos A, Tinahones FJ, Peñafiel R. Dietary and gut microbiota polyamines in obesity- and age-related diseases. Front Nutr. 2019;6:24. https://doi.org/10.3389/fnut.2019.00024.
Roager HM, Licht TR. Microbial tryptophan catabolites in health and disease. Nat Commun. 2018;9(1):3294. https://doi.org/10.1038/s41467-018-05470-4.
Sagar NA, Tarafdar S, Agarwal S, Tarafdar A, Sharma S. Polyamines: functions, metabolism, and role in human disease management. Med Sci. 2021;9(2):44. https://doi.org/10.3390/medsci9020044.
Sansome DJ, Xie C, Veedfald S, Horowitz M, Rayner CK, Wu T. Mechanism of glucose-lowering by metformin in type 2 diabetes: role of bile acids. Diabetes Obes Metab. 2020;22(2):141–8. https://doi.org/10.1111/dom.13869.
Serena C, Ceperuelo-Mallafré V, Keiran N, Queipo-Ortuño MI, Bernal R, Gomez-Huelgas R, Urpi-Sarda M, Sabater M, Pérez-Brocal V, Andrés-Lacueva C, Moya A, Tinahones FJ, Fernández-Real JM, Vendrell J, Fernández-Veledo S. Elevated circulating levels of succinate in human obesity are linked to specific gut microbiota. ISME J. 2018;12(7):1642–57. https://doi.org/10.1038/s41396-018-0068-2.
Shen Y-L, Zhang L-Q, Yang Y, Yin B-C, Ye B-C, Zhou Y. Advances in the role and mechanism of lactic acid bacteria in treating obesity. Food Bioeng. 2022;1(1):101–15. https://doi.org/10.1002/FBE2.12002.
Taormina VM, Unger AL, Schiksnis MR, Torres-Gonzalez M, Kraft J. Branched-chain fatty acids – an underexplored class of dairy-derived fatty acids. Nutrients. 2020;12(9):2875. https://doi.org/10.3390/nu12092875.
Velasquez MT, Ramezani A, Manal A, Raj DS. Trimethylamine N-oxide: the good, the bad and the unknown. Toxins. 2016;8(11):326. https://doi.org/10.3390/TOXINS8110326.
Verbeke KA, Boobis AR, Chiodini A, Edwards CA, Franck A, Kleerebezem M, Nauta A, Raes J, van Tol EAF, Tuohy KM. Towards microbial fermentation metabolites as markers for health benefits of prebiotics. Nutr Res Rev. 2015;28(1):42–66. https://doi.org/10.1017/S0954422415000037.
Visekruna A, Luu M. The role of short-chain fatty acids and bile acids in intestinal and liver function, inflammation, and carcinogenesis. Front Cell Dev Biol. 2021;9:703218. https://doi.org/10.3389/fcell.2021.703218.
Wahlström A, Sayin SI, Marschall HU, Bäckhed F. Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. Cell Metab. 2016;24(1):41–50. https://doi.org/10.1016/j.cmet.2016.05.005.
Wang C, Zhu C, Shao L, Ye J, Shen Y, Ren Y. Role of bile acids in dysbiosis and treatment of nonalcoholic fatty liver disease. Mediat Inflamm. 2019;2019:7659509. https://doi.org/10.1155/2019/7659509.
Wu Y, Xu H, Tu X, Gao Z. The role of short-chain fatty acids of gut microbiota origin in hypertension. Front Microbiol. 2021;12:730809. https://doi.org/10.3389/fmicb.2021.730809.
Xiang H, Sun D, Liu X, She ZG, Chen Y. The role of the intestinal microbiota in nonalcoholic steatohepatitis. Front Endocrinol. 2022;13:812610. https://doi.org/10.3389/fendo.2022.812610.
Yang S, Li X, Yang F, Zhao R, Pan X, Liang J, Tian L, Li X, Liu L, Xing Y, Wu M. Gut microbiota-dependent marker TMAO in promoting cardiovascular disease: inflammation mechanism, clinical prognostic, and potential as a therapeutic target. Front Pharmacol. 2019;10:1360. https://doi.org/10.3389/FPHAR.2019.01360.
Zhou, D., Zhang, J., Xiao, C., Mo, C., & Ding, B. sen. (2022). Trimethylamine-N-oxide (TMAO) mediates the crosstalk between the gut microbiota and hepatic vascular niche to alleviate liver fibrosis in nonalcoholic steatohepatitis. Front Immunol, 13, 964477. https://doi.org/10.3389/FIMMU.2022.964477.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2024 Springer Nature Switzerland AG
About this entry
Cite this entry
Fernández-Veledo, S., Marsal-Beltran, A., Ceperuelo-Mallafré, V., Astiarraga, B., Cedó, L. (2024). The Impact of Microbial Metabolites on Host Health and Disease. In: Federici, M., Menghini, R. (eds) Gut Microbiome, Microbial Metabolites and Cardiometabolic Risk. Endocrinology. Springer, Cham. https://doi.org/10.1007/978-3-031-35064-1_3
Download citation
DOI: https://doi.org/10.1007/978-3-031-35064-1_3
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-35063-4
Online ISBN: 978-3-031-35064-1
eBook Packages: MedicineReference Module Medicine